), 1 and their suggestion that this topic was somewhat neglected in our recent Review on cancer immunotherapy (Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 11, 24-37 [2014]).
CORRESPONDENCE
We appreciate very much the correspondence from Shin 2 In their thoughtful letter, they highlight several murine and human in vitro studies suggesting that manipulation of T REG number and/or function may be an important consequence of immune checkpoint blockade. In that regard, we concur completely with their assessment that the effects of CTLA-4 blockade in regulating T REG of patients with cancer remains unclear. Whereas two recent animal studies 3, 4 showed that anti-CTLA-4 antibodies can deplete T REG that express relatively high levels of CTLA-4, the clinical relevance of these data is slightly undermined by the clinical observation that poly morph isms of human Fc receptors (FcRs) did not seem to correlate with the efficacy of anti-CTLA-4 in a fairly large series of patients with melanoma; such a correlation might be expected if FcR-mediated T REG depletion was the major mechanism by which this agent functions. 5 In vitro studies of human T cells treated with anti-PD-1 or
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anti-PD-L1 antibodies showed a decreased expression of FOXP3 in T REG ; 6 however, to our knowledge these findings have not yet been replicated in vivo or in patients treated with monoclonal antibodies to PD-1 and/ or PD-L1 in clinical trials. Perhaps the most important challenge in cancer immunotherapy involving T REG manipulation is that there are still no extra cellular molecules absolutely speci fic to T REG ; the vast majority of these mol ecules are, in fact, expressed on activated CD4 T cells as well. Furthermore, targeting T REG with antibodies directed against C-C chemokine receptor type (CCR-4) 7 or even to lymphocyte activation gene 3 protein (LAG-3)
8 is a viable clinical strategy; however, these approaches are in a relatively earlier stage of development compared to the immune checkpoint and vaccine regimens discussed in our Review.
Nevertheless, we are in complete concurrence with Shin & Ha that a combined immuno therapy regimen-which includes specific targeting of T REG -represents a promising strategy, particularly for either advanced-stage disease or for the many tumour types that have not shown objective responses to single-agent immune checkpoint blockade.
